Managing specific symptoms in people with multiple sclerosis.
Besides immunomodulation and immunosuppression, symptomatic treatment is an important part of MS therapy. Its goals are the elimination and reduction of symptoms that impair functional ability and quality of life, and also the avoidance of secondary complications. There are many treatment recommendations for MS symptoms, therefore clear and consensually developed therapeutic strategies are needed. This paper reviews some recommendations for the treatment of MS-related spasticity, fatigue, pain and neurogenic bladder dysfunction that have been established by the Multiple Sclerosis Treatment Consensus Group of the German MS Society.
Henze
T
T
Klinik am Regenbogen, Fachklinik für Neurologische Rehabilitation, Eichendorffstr. 21, D-93149 Nittenau, Germany. t.henze@klinikamregenbogen.de
D005221:Fatigue / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D009128:Muscle Spasticity / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D010146:Pain / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D001750:Urinary Bladder, Neurogenic / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control